New drug adds to arsenal against AIDS

July 15, 2011

A new drug, rilpivirine, can add powerfully to the combination of medications used to control HIV for first-time patients, researchers conclude in Friday's issue of The Lancet.

Rilpivirine, marketed by pharmaceutical firm Tibotec under the brand name of Edurant, is both safe and effective and its side effects are fewer and less severe compared with the widely-used efavirenz, or Sustiva, they say.

Combination therapy for new commonly entails giving either efavirenz or nevirapine in conjunction with drugs of a separate class in order to attack the (HIV) from different angles.

Efavirenz and nevirapine are equally effective at suppressing HIV but can cause severe side effects, which is why there has been a search for a substitute drug in their class.

The two studies report on data from two trials carried out among nearly 1,400 patients in 21 countries.

Rilpivirine, a so-called second generation antiretroviral, was approved for combination therapy in May by the (FDA).

The study appears in the runup to a four-day medical conference, starting in Rome on Sunday, on the state of the HIV/AIDS pandemic.

Acquired immune deficiency syndrome (AIDS) has claimed some 30 million lives since the first recorded cases emerged in June 1981. At least 33 million people are living with HIV, according to UN estimates for 2009.

Explore further: FDA approves antiretroviral drug

Related Stories

FDA approves antiretroviral drug

August 7, 2007

The U.S. Food and Drug Administration has approved the antiretroviral drug maraviroc for use in adult human immunodeficiency virus patients.

US approves new HIV drug

May 21, 2011

The US Food and Drug Administration on Friday approved a new drug, Edurant, to fight HIV in combination with other antiretrovirals already on the market.

Recommended for you

Mutational tug of war over HIV's disease-inducing potential

August 23, 2016

A study from Emory AIDS researchers shows how the expected disease severity when someone is newly infected by HIV reflects a balance between the virus' invisibility to the host's immune system and its ability to reproduce.

Dormant copies of HIV mostly defective, new study shows

August 8, 2016

After fully sequencing the latent HIV "provirus" genomes from 19 people being treated for HIV, scientists at Johns Hopkins Medicine report that even in patients who start treatment very early, the only widely available method ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.